Early-Stage OT-82 Developed by Roswell Park Comprehensive Cancer Center & Shows Promise to Fight High-Risk Leukemia

Early-Stage OT-82 Developed by Roswell Park Comprehensive Cancer Center & Shows Promise to Fight High-Risk Leukemia

OT-82, a preclinical stage drug candidate developed at Roswell Park Comprehensive Cancer Center (RPCCC) Buffalo, shows promise as a treatment to fight high-risk leukemia. Licensed for R&D and commercialization to OncoTartis, a biotech venture organized by RPCCC’s professor Andrei Gudkov, they announced positive preclinical research evidence generated by a collaboration with Australia’s Children’s Cancer Institute with the announcement of published results in journal Leukemia. OT-82 is now in a Phase I clinical trial. The IP has the attention of a Russian Billionaire and the largest Russian pharmaceutical company—both representing the first major venture investment in the sponsor.

A Potentially Powerful New Weapon Against Blood Cancers?

A significant proportion of blood cancers in both adults and children remain resistant to current treatments and are often deadly. Someone dies from some form of blood cancer in the United States every 9 minutes according to the Leukemia & Lymphoma Society.

The Investigational Drug: OT-82

OT-82, a NAMPT (NicotinAMide Phosphoribosyl Transferase) inhibitor, was originally developed at Buffalo, New York’s Roswell Park Comprehensive ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee